

STUART L. SILVERMAN, MD, FACP, FACR

CURRICULUM VITAE

September 2011

Professional Contact Information:

Stuart L. Silverman, MD - A Medical Corporation
8641 Wilshire Blvd., Suite 301 Beverly Hills, CA 90211
Phone: 310-358-2234
Fax: 310-659-2841
Email: stuarts@omcresearch.org

The Osteoporosis Medical Center - A California Nonprofit Research Corporation
8641 Wilshire Blvd., Suite 301 Beverly Hills, CA 90211
Phone: 310-358-5757
Fax: 310-358-9226
Email: stuarts@omcresearch.org

Education:

- The Johns Hopkins University Medical School, 1973
- Princeton University, B.A., Cum Laude in Biology, 1965-1969
- University Scholar, 1969

Licensure:

California, C39893

Board Certification:

- Co-joint Board of Allergy & Immunology, 1980
- American Board of Rheumatology, 1978
- American Board of Internal Medicine, 1976

Professional Experience:

- President, Stuart L. Silverman, MD - A Medical Corporation, 1981-Present

Professional Activities: Society Memberships and Committee Services

- Fellow, American College of Rheumatology
- American Society of Bone and Mineral Research
- Phi Delta Epsilon
- Fellow, American College of Physicians
- American Federation for Clinical Research
- American Rheumatism Association

Editorial Boards to Scholarly Publications (Serving as a Reviewer or Editor)

- Journal of Bone Mineral Research
- Future Rheumatology
- Current Rheumatology Reports, Section Editor
- Therapeutic Advances in Musculoskeletal Disease

- Journal of Osteoporosis
- Osteoporosis International

Advisory Boards

- Lilly Osteoporosis Advisory Board
- Alliance for Bone Health SW ROB
- Merck Rheumatology Advisory Board in Osteoporosis
- Zolendronate Rheumatology Advisory Board (Novartis)
- Amgen Osteoporosis Registry
- Novartis ONJ Advisory Board
- Roche Global Advisory Board
- ASBMR ONJ Task Force Member
- ASBMR Systemwide Intervention Task Force
- ACR GIO Guidelines Task Force Member
- ACR Quality Measure Committee, Member
- ACR Quality Measure in Glucocorticoid Induced Osteoporosis Task Force, Member

CSMC Professional Activities:

Medical Director, Cedars-Sinai Bone Center of Excellence, November 2010-Present

Research Grants and Fellowships Received: (direct costs; you are component only if multiple Co-PIs)

1. NIH. "Activating Patients to Reduce Osteoporosis (APROPOS)." \$3,704,921.00 July 1, 2011-June 31, 2016. Role as Consultant. 0.9% effort for each grant.
2. GLOW. "Global Longitudinal Registry of Osteoporosis in Women (GLOW)." \$335,150.00 January 2007-January 2012. Role as Principal Investigator for the Western Region. 0.12% effort for each grant.
3. IOF. "International Costs and Utilities related to Osteoporosis Fractures Study (ICUROS-US)." \$945,654.74 September 2007-December 2012. Role as Principal Investigator. 0.24% effort for each grant.
4. Novartis. "Racial and Ethnic preferences for osteoporosis treatments." \$76,000. October 2010-October 2011. Role as co-PI with Deborah Gold, PhD. 0.24% effort for each grant.
5. Pfizer, Inc. "Examination of Pregabalin Access for Treatment of Indicated Pain Disorders: The EXPAND Study." \$8,000. May 2011-December 2011. Role as Principal Investigator. 0.24% effort for each grant.
6. Pfizer, Inc. "Fixed versus flexible dosing of Pregabalin in patients with fibromyalgia." \$361,000. October 2010-October 2012. Role as Principal Investigator for IIRP. 0.6% effort for each grant.
7. Watson Laboratories, Inc. "A multi-center, double-blind, randomized, parallel-group, placebo controlled study to determine the therapeutic equivalence of a generic diclofenac sodium topical gel 1% and Voltaren® Gel in subjects with

osteoarthritis of the knee.” \$31,200. May 2011-December 2011.
Role as Principal Investigator. 0.6% effort for each grant.

**Research Projects and
Research Focus or
Interest**

1. **Osteoporosis epidemiology.**
 - a. ICUROS (International Costs and Utilities related to Osteoporosis Fractures), a global IOF sponsored study.
 - b. Secular Trends in Hip Fractures Incidence in California 1983-2000 for Different Ethnic Groups, co-author with Dave Zingmond.
2. **Patient preferences.**
 - a. Racial and ethnic differences in patients weighing of medication attribute. Study with Duke University. Sponsored by Novartis.
3. **Quality of Life in Osteoporosis.**
 - a. Developer of OPAQ (Osteoporosis Assessment Questionnaire) first disease specific HXQOL question. Have analyzed OPAQ data in multiple clinical trials (MORE, PTH, FREEDOM).
4. **Adherence to medications.**
 - a. Author multiple studies based on claims data and observational data.
 - b. Co-author with Jeff Curtis of UAB and Ethel Siris. Development of predictive rule for poor adherence based on GLOW (The Global Longitudinal Study of Osteoporosis in Women).
 - c. Co-author of validation study of an osteoporosis specific measure of adherence (OSMMAS).
5. **Glucocorticoid osteoporosis.**
 - a. A member ACR task force on GIO guidelines.
 - b. Lead author, GIO management globally in GLOW (The Global Longitudinal Study of Osteoporosis in Women).

**Invited Lectures and
Presentations
(International):**

1. “Mechanism and Management of Chronic Pain: Lessons from Fibromyalgia.” Invited Rheumatology Oration. Lucknow, India. October 2010.
2. “Adherence, Clinical Use of Bone Markers”. ISCD. Orlando, Florida. March 2009.
3. “Adherence”. ECCEO IOF. Athens, Greece. March 2009.
4. “Quality of Life, Symposium on Clinical Use of Bone Markers”. NOF International Symposium on Osteoporosis. Washington, DC. April 2009.
5. “Adherence, Role of Observational Studies, Quality of Life, Meet the Professor on Clinical Utility of Bone Markers.” Colombian Osteology and Mineral Society. Medellin, Columbia. May 2009.
6. “Clinical Utility of Bone Markers.” South China Osteoporosis Forum. Shanghai, China. July 2009.
7. “Identifying and Treating Patients with Osteoporosis.” Turkish

- National Endocrinology Congress. Belek, Antalya, Turkey. September 2006.
8. "New Developments in Bisphosphonates." Turkish National Geriatric Congress. Beldibi, Kermer, Turkey. September 2006.
 9. "New Developments in Therapy of Osteoporosis." Turkish National Rheumatology Congress. Cesmes, Izmir, Turkey. September 2006.
 10. "Preferences and Patient Satisfaction." Roche Expert Meeting. Montreux, Switzerland. December 2005.
 11. "Vertebral Osteoporosis: The Downward Spiral." First WHO collaborating center Asian regional conference on osteoporosis. Singapore. March 2004.
 12. "Preclinical and Clinical Studies of Analgesic Efficacy of Calcitonin." Novartis Expert Meeting. Istanbul, Turkey. 2003.
 13. "How Do Antiresorptive Therapies Work to Reduce Fractures?" 3rd German/Turkish Congress in Conflicts & Controversies in Gynecology. Antalya, Turkey. 2003.
 14. "Estrogen or raloxifene for postmenopausal osteoporosis therapy?" 3rd International meeting of Controversies in Obstetrics, Gynecology and Infertility. Washington, DC. 2002.
 15. "Postmenopausal Osteoporosis: A Call to Action." Korean Osteoporosis Association. Seoul, Korea. November 2001.
 16. "Antiresorptive Therapies: Clinical Applications." Canadian Society of Obstetrics and Gynecology. St John's Newfoundland, Canada. June 2000.
 17. "The PROOF Study" and "Quality of Life in Osteoporosis." First Pan Arab Conference in Osteoporosis. Beirut, Lebanon. October 2000.
 18. "Meet the Professor: Quality of Life." World Congress in Osteoporosis. Chicago, IL. June 2000.
 19. "The PROOF Study" and "Osteoporosis and Bone Quality." Taiwan Osteoporosis Society. Taipei. June 2000.

Invited Lectures and Presentations (National):

1. "Pathophysiology of Pain: Mechanisms & Manifestations." American College of Physicians. San Diego, California. April 2011.
2. "Invited Plenary Lecture, Long Term Consequences of Anti-Resorptive Therapy." American College of Rheumatology. Atlanta, Georgia. November 2010.
3. "Identifying at risk patient for osteoporosis." Meet the Professor Workshop, American College of Rheumatology. Atlanta, Georgia. November 2010.
4. University of Cincinnati "Bone Day." University of Cincinnati. Cincinnati, Ohio. April 2006.
5. "Dysautonomia in Fibromyalgia." National Fibromyalgia Association Conference. Anaheim, California. March 2006. California Long Island Bone Club. Anaheim, California. February 2006.

6. "Absolute Risk." Northern California Institute for Bone Health. Berkeley, California. December 2005.
7. "Monitoring Osteoporosis." Satellite Symposium at NAMS. San Diego, California. September 2005.
8. "New WHO risk factor paradigm." Meet the Professor at ASBMR. San Diego, California. September 2005
9. "BMD and Bone turnover." ASBMR Satellite Symposium. San Diego, California. September 2005.
10. "Measuring Quality of Life in Osteoporosis." Meet the Professor at NOF. Washington, DC. April 2005.
11. "Identifying women who will benefit from osteoporosis treatment." Satellite Symposium at AACE. May 2004.
12. "Role of Vertebral Augmentation in the Management of Osteoporotic Vertebral Compression Fractures." ACR Metabolic Bone Disease Study Group. (Location). 2003.
13. "Osteoporosis: There are Choices for Treatment." Texas Academy of Family Physicians. San Antonio, Texas. February 2002.
14. "Osteoporosis Therapies 2002: New Concepts." Arizona Rheumatology Associates. Arizona. February 2002.
15. "Clinical Applications of Antiresorptive Therapies." Grand Rounds, Straub Medical Center. Honolulu, Hawaii. November 2001.
16. "Multidisciplinary Treatment of Fibromyalgia", "Pharmacological Treatment of Fibromyalgia" and "Research Update: Pregabalin and Tramadol". 2nd Annual FAME conference. Chicago, Illinois. June 2001.
17. "Clinical Applications of Antiresorptive Therapies." American College of Rheumatology Satellite Symposium. October 2000.
18. "SERMS and their effects on bone." American Academy of Physician Assistants. Chicago, Illinois. May 2000.
19. Hartford AFAR Visiting Professor in Geriatrics University North Texas. Fort Worth, Texas. April 2000.
20. "Treating Osteoporosis." American Society for Aging. San Diego, California. March 2000.
21. "Choices for Osteoporosis Therapy." Medical Grand Rounds, North Colorado Medical Center. Greeley, North Colorado. February 2000.
22. "Decision Making for the Menopausal Patient." North Colorado NP, PA Society. Fort Collins, Colorado. February 2000.

Invited Lectures and Presentations (Local and Regional):

1. "Atypical Fractures." Radiology Grand Rounds, Cedars- Sinai. October 2010.
2. "Atypical Fractures." Orthopedic Grand Rounds, Cedars Sinai. October 2010.
3. "Oral Bisphosphonate Therapy for Osteoporosis and its Impact on Oral Health." California Dental Association. Anaheim,

- California. May 2008.
4. "Osteoporosis Update." Klinenberg Symposium. Cedars Sinai. March 2006.
 5. "Managing Pain in Fibromyalgia." California Medical Association. Anaheim, California. January 2006.
 6. "Osteoporosis Update." Klinenberg Symposium. Cedars Sinai. March 2005.
 7. "Management of Fibromyalgia." California Society of Addiction Medicine. Anaheim, California. October 2005.
 8. "Focus on osteoporotic fracture." Orthopedic division, Arrowhead Regional Medical Center. Arrowhead, California. October 2005.
 9. "Fibromyalgia." Rheumatology Grand Rounds, UCLA Medical Center. August 2005.
 10. "Osteoporosis." Medical Conference West Los Angeles VA. May 2005.
 11. "Osteoporosis." Medical Grand Rounds, Cedars-Sinai. May 2005.
 12. "Managing Osteoporosis." Cedars-Sinai, Dept. of Medicine. March 2005.
 13. "Osteoporosis Case Management." Noon Medical Conference, Health care Partners. Los Angeles, California. February 2005.
 14. "Osteoporosis: who to treat?" Endocrine Grand Rounds, Cedars-Sinai. January 2005.
 15. "Fibromyalgia." Medical Grand Rounds, Cedars-Sinai. May 2004.
 16. "Osteoporosis Update." UCLA Harbor General. May 2004.
 17. "Fibromyalgia." Rheumatology Conference, UCLA.
 18. "Epidemiology and Quality of Life in Osteoporosis." UCLA Rheumatology Research Conference. September 2003.
 19. "Choices for Osteoporosis Therapy." San Diego Academy of Family Physicians. San Diego, California. June 2002.
 20. "How to Treat and Diagnose Fibromyalgia." Klinenberg Symposium. Los Angeles, California. March 2002.
 21. "Clinical Applications of Osteoporosis Therapies." Grand Rounds, St. Joseph Hospital. Orange, California. December 2001.
 22. "Osteoporosis Treatment." UCLA Grand Rounds. December 2001.
 23. "Parathyroid Hormone: A New Anabolic Osteoporosis Treatment." Rheumatology Ground Rounds, Cedars-Sinai. September 2001.
 24. "PTH. San Diego Bone Club. June 2000.
 25. Anabolic Therapies. Endocrine Grand Rounds, San Diego VA. June 2000.
 26. Osteoporosis therapy. Rheumatology Division Grand Rounds, USC. 2000.
 27. Osteoporosis, a Call to Action. Medical Grand Rounds, Long Beach Memorial Hospital. August 31, 2000.
 28. Osteoporosis, New Medicines, New Concepts. Primary Care Rheumatology, Cedars Sinai. March 4, 2000.

CSMC Teaching Activities and/or Other off-campus teaching (e.g. UCLA, King Drew, Harbor-UCLA, WLA VA, and other institutions):

1. Attending Outpatient Rheumatology Clinic, 1 month yearly, half day per week.
2. Mentoring of Rheumatology Fellows and Women Health Fellows, 2 days per week for 1 month for each fellow in office.

BIBLIOGRAPHIES / PUBLICATIONS

Research Papers (Peer Reviewed)

1. Silverman, S.L., Constine, L., Harvey, D., & Grahame, R., "Survey of Joint Mobility and in vivo Skin Elasticity in London Schoolchildren," *Ann Rheum Dis*, 34:177-180, 1975.
2. Silverman, S.L., Scheinberg, M., Yonkosky, D., & Cathcart, E.S., "Monocyte Involvement in PHA Induced Cytotoxicity of Chicken Erythrocytes in Man" *Cell. Immunol.* 22:93-97, 1976.
3. Yonkosky, D., Silverman, S.L., & Cathcart, E.S., "Mitrogen-Induced Cellular Cytotoxicity, (MICC) in Multiple Myeloma," *J. Immunol.* 228:947-951, 1977.
4. Pastan, R., Silverman, S.L., & Goldenberg, D., "A Musculoskeletal Syndrome in Intravenous Drug Users Associated with Brown Heroin," *Ann. Int. Med.* 89:207-211, 1977.
5. Adams, W., Rufo, R., Silverman, S.L., & Brauer, M., "Thrombo-Cytopenia in Intravenous Drug Users," *Ann. Int. Med.*, 89:207-211, 1978.
6. Levy, E., Silverman, S.L., Achmed, K., & Cooperband, S., "MICC Activity of Human Monocytes," *Cell Immunol.* 40:222-229, 1978.
7. Silverman, S.L., Cathcart, E.S., Skinner, M., & Cohen, A.S., "A Pathogenic Role for Polymorphonuclear Cells in the Synthesis and Degradation of SAA Protein, "Proceedings of the Third International Symposium on Amyloidosis. *Excerpta Medica, Amsterdam* 79:420-425.
8. Silverman, S.L., & Cathcart, E.S., "Natural Killing in SLE: Inhibitory Effect of Serum," *Immunol. Immunopath.* 17:226-229, 1980.
9. Silverman, S.L., & Schumacher, H.R., "Antibodies to Epstein Barr Viral Antigens in Early Rheumatoid Arthritis," *Arthritis Rheum.* 24:1465-1468, 1981.
10. Silverman, S.L., Cathcart, E.S., Skinner, M., & Cohen, A.S., "The Polymorphonuclear Leucocyte in the Pathogenesis of Amyloidosis, The Role of Granulocyte Elastase," *Immunol.* 46:737-744, 1982.
11. Silverman, S.L., & Madison, R.E., "Decreased Incidence of Hip Fracture in Hispanics, Blacks and Asians," *Am. J. Public Health*, 78:1482-1483, 1988.
12. Potts, M.K., & Silverman, S.L., "The Importance of Aspects of Treatment for Fibromyalgia (fibrositis): Differences Between Patient and Physician Views," *Arthritis Care and Research*, 3:11-18, 1990.
13. Silverman, S.L., "Clinical Etiology and Treatment of Steroid-Induced Osteoporosis," *J. Musculoskeletal Med.* 7(7):14-27, 1990.
14. Brandli, D., Silverman, S.L., & Greenwald, M. "Corticosteroid-Induced Osteoporosis: A Cross Sectional Study," *Steroids.* 56:517-523, 1991.
15. Silverman, S.L., "Management of Osteoporosis, A Clinician's Perspective,"

- editorial, *Calcified Tissue International*, 50:101-103, 1992.
16. Silverman, S.L., "The Functional Impact of Fibromyalgia," *J. Musculoskeletal Med.* 1992; 9(7):15-24.
 17. Silverman, S.L., "Clinical Consequences of Vertebral Fracture," *Bone*, 1992; 5:S27-S31.
 18. Brandli, D., Greenwald, M., & Silverman, S.L., "Fluoride Treatment of Steroid-Induced Osteoporosis," *Osteop. Intl*, 2:303-304, 1992.
 19. Greendale, G., Silverman, S., Hays, R., et.al. "Health Related Quality of Life in Osteoporosis," *Calcified Tissue International*. 53:75-77, 1993.
 20. Silverman, S.L., "Using Drugs Effectively in the Treatment of Fibromyalgia," *J. Musculo Skeletal Med.*, 1994; 11(12):29-34.
 21. Wallace, D.J., Silverman, S.L., Goldstein, J., Hughes, D., "The Use of Hyperbaric Oxygen in Rheumatic Diseases: Case Report and Critical Analysis," *LUPUS* (1995) 4, 172-175.
 22. Silverman, S.L., Vescio, R., Silver, D., Renner, S., Weiner, S., Berenson, J.: "Silicone Gel Implants and Monoclonal Gammopathies: Three cases of Multiple Myeloma and the Prevalence of Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance," *Immunology of Silicones* (1995), 367-374.
 23. Silverman, S.L., Gluck, O., Silver, D., Tesser, J., Wallace, D., Neuman, K., Metzger, A., Morris, R., "The Prevalence of Autoantibodies in Symptomatic and Asymptomatic Patients with Breast Implants and Patients with Fibromyalgia," *Immunology of Silicones* (1995), 317-322.
 24. Rabkin, C.S., Silverman, S., Tricot, G., Garland, L.L., Ballester, O., Potter, M., "The National Cancer Institute Silicone Implant/Multiple Myeloma Registry Current Topics In Microbiology and Immunology", *Immunology of Silicones* (1995), 385-388.
 25. Silverman, S., as member of the Vancouver Fibromyalgia Consensus Group: "The Fibromyalgia Syndrome: A Consensus Report on Fibromyalgia and Disability," *J. Rheum* 1996, 23:3.
 26. Silverman, S., as member of the Department of Veterans Affairs Cooperative Study, "Comparison of Sulfasalazine and Placebo in the Treatment of Ankylosing Spondylitis," *Arth & Rheum* 1996, 39:12, 2004-2012.
 27. Silverman, S., as member of a Department of Veterans Affairs Cooperative Study, "Comparison of Sulfasalazine and Placebo in the treatment of Psoriatic Arthritis" *Arth & Rheum* 1996, 39:12, 2013-2020.
 28. Silverman, S., "Therapy of Osteoporosis III: Calcitonin," *Am. J. Med. Sci.* 1997; 313(1):13-16.
 29. Silverman, S., (as member of a Department of Veterans Affairs Cooperative Study), "Comparison of Sulfasalazine and Placebo in the treatment of Reactive Arthritis (Reiter's Syndrome)," *Arth & Rheum* 1996, 39:12, 2021-2027.
 30. Silverman SL, Cranney A. Quality of Life Measurements in Osteoporosis. *J Rheumatol.* 1997 Jun; 24(6): 1218-21.
 31. Silverman, S., as member of the Vancouver Fibromyalgia Consensus Group "The Fibromyalgia Consensus Report: Additional Comments", *J. Rheum.* 1997. 3:6, 324-327.

32. Silverman, S., & Drinkwater, B., "Effect of Bone Density Information On Decision making About Estrogen", *Obstetrics & Gynecology*, 89:3 (321-325)
33. Melton, III, L.J., Thamer, M., Ray, N.F., Chan, J.K., Chesnut, III, C.H., Einhorn, T. A., Johnston, C.C., Raisz, L.G., Silverman, S.L., and Siris, E.S., "Fractures Attributable to Osteoporosis: Report from the National Osteoporosis Foundation", *J. Bone Min Res.* 1997. 12(1): 16-23.
34. Silverman SL. Nasal Calcitonin. *Endocrine.* 1997 Apr; 6(2): 199-202.
35. Genant, H.K., Maricic, M.J., Silverman, S.L., Silverton, S., Wallach, S., "Osteoporosis, A Treatment Approach to Long-Term Care Patients" *Nursing Home Medicine, the Annals of Long-term Care.* 1997; Suppl. G
36. Silverman, S.L., "Quality of Life Measurement in Osteoporosis", *MAPI Quality of Life Newsletter* 1997:18.
37. Randell AG, Bhalerao N, Nguyen TV, Sambrook PN, Eisman JA, Silverman SL. Quality of Life in Osteoporosis: Reliability, Consistency and Validity of the Osteoporosis Assessment Questionnaire. *J Rheumatol.* 1998 Jun; 25(6): 1171-9.
38. Silverman SL as a member of the VERT study group. Effects of Risedronate Treatment on Vertebral and Nonvertebral Fractures in Women with Postmenopausal Osteoporosis: A Randomized Controlled Trial. *JAMA* 282:1344-1352, 1999.
39. Randell, AG, Nguyen TV, Bhalerao N, Silverman SL, Sambrook PN, Eisman JA. Deterioration in quality of life following hip fracture: a prospective study. *Osteoporosis Int.* 2000; 11(5): 460-6.
40. Chesnut CH, Silverman SL, Andriano K, Genant H, Gimona A, Harris A, Kiel D, LeBoff M, Maricic M, Miller P, Moniz C, Peacock M, Richardson P, Watts N, Baylink D, for the PROOF Study Group: "Prospective, Randomized Trial of Nasal Spray Calcitonin in Postmenopausal Women with Established Osteoporosis: the PROOF Study". *American Journal of Medicine.* Sept. 2000; 109: 267-276.
41. Silverman SL. The Osteoporosis Assessment Questionnaire (OPAQ): A Reliable and Valid Disease-Targeted Measure of Health Related Quality of Life (HRQOL) in Osteoporosis. *Quality of Life Research* 9: 767-774, 2000.
42. Lindsay R, Silverman SL, Cooper C, Hanley DA, Barton I, Broy SB, Licata A, Benhamou L, Geusens P, Flowers K, Stracke H, Seeman E. Risk of New Vertebral Fracture in the Year Following a Fracture. *JAMA.* 2001 Jan; 285(3): 320-3.
43. Hallegua DS, Wallace DJ, Silverman SL, Bonert V, Mathur R, Klinenberg JR "Prevalence of Fibromyalgia in Growth Hormone Deficient Adults" in *Journal of Musculoskeletal Pain* Vol 9(3) 2001.
44. Silverman SL, Schein JR: "Physician-patient decision making in Osteoporosis Management" *J Musc Skel Med.* 2001; 18(3): 124-130.
45. Adachi JD, Adami S, Miller PD, Olszynski WP, Kendler DL, Silverman SL, Licata AA, Li Z, Gomez-Panzani E. Tolerability of Risedronate in Postmenopausal Women Intolerant of Alendronate. *Aging (Milano).* 2001 Oct; 13(5): 347-54.
46. Silverman SL, Minshall ME, Shen W, Xie S; Health Related Quality of Life

- Subgroup of the Multiple Outcomes of Raloxifene Evaluation Study. The Relationship of Health-Related Quality of Life to Prevalent and Incident Vertebral Fractures in Post-Menopausal Women with Osteoporosis: Results from the Multiple Outcomes of Raloxifene Evaluation (MORE) Study. *Arthritis Rheum.* 2001 Nov; 44(11): 2611-9.
47. Silverman S. "Physical and Psychosocial Consequences of Osteoporotic Vertebral Fracture (Part 1). Quality-of-Life: What the Studies and Instruments Tell Us." *Advances in Osteoporotic Fracture Management* Vol.1 No 2 2001.
 48. Greenwald B, Bardwell A, Malinak J, Rude R, Silverman SL, White-Greenwald M: "New Bone Density Report Format Influences Patient Compliance in Filling Prescriptions for Osteoporosis". *Clin. J of Women's Health* Vol 2 No 1. 2002.
 49. Wallace DJ, Linker-Israeli M, Hallegua D, Silverman S, Silver D, Weisman MH: "Cytokines play an aetiopathogenic role in fibromyalgia: a hypothesis and pilot study" *Rheumatology.* 2001; 40:743-749.
 50. Silverman SL, Wong M: "Estrogen or Raloxifene for Postmenopausal Osteoporosis Therapy?" *Third World Congress on Controversies in Obstetrics, Gynecology & Infertility* June, 2002, 55-58.
 51. Silverman SL, Azria M: "The Analgesic Role of Calcitonin Following Osteoporotic Fracture" *Osteoporosis International* (2002). 13:858-867.
 52. Oglesby AL, Minshall ME, Shei W, Xie S, Silverman SL: " The Impact of Incident Vertebral and Non-Vertebral Fragility Fractures on Health-Related Quality of Life in Established Postmenopausal Osteoporosis: Results from the Teriparatide Randomized, Placebo-Controlled Trial in Postmenopausal Women" *J. Rheum* 2003; 30:7:1579-1583.
 53. Silverman SL: Fracture, Cardiovascular, and Breast Cancer Event Rates at 3 Years in Postmenopausal Women with Osteoporosis: Results from the Placebo Group of the Multiple Outcomes of Raloxifene Evaluation (MORE) Trial. *J Amer Geriatric Soc.* 2004; 97: 50-4.
 54. Zingmond D, Melton LJ, Silverman SL. "Increasing hip fracture incidence in California Hispanics, 1983 to 2000". *Osteoporosis Int.* 2004 Aug; 15(8):603-10.
 55. Gold DT, Silverman SL, Miller BE. *Osteoporosis Self Management: Choices for Better Bone Health.* *Southern Med J* 2004 97(6): 551-554.
 56. Silverman SL, Delmas PD, Kulkarni PM et al.: Comparison of Fracture, Cardiovascular and Breast Cancer Event Rates at 3 Years in Postmenopausal Women with Osteoporosis. *J Amer Geriatr Soc* 2004.
 57. Crans GG, Silverman SL, Genant HK, Glass EV, Krege JH. Association of Severe Vertebral Fractures with Reduced Quality of Life: Reduction in the Incidence of Severe Vertebral Fractures by Teriparatide. *Arthritis Rheum.* 2004 Dec; 50(12): 4028-34.
 58. Miller PD, Silverman SL, Gold DT, Taylor KA, Chen P, Wagman RB. Rationale, objectives and design of the Direct Analysis of Nonvertebral Fracture in the Community Experience (DANCE) Study. *Osteoporosis Int.* 2006 Jan; 17(1): 85-90.
 59. Manicourt DH, Devogelaer JP , Azria M, Silverman SL. Rationale for the potential use of calcitonin in osteoarthritis. *J Musculoskelet Neuronal*

- Interact 2005; 5(3):285-294.
60. Silverman SL, Piziak VK, Chen P, Misurski DA, Wagman RB. Relationship of health related quality of life to prevalent and new or worsening back pain in postmenopausal women with osteoporosis. *J Rheumatol* 2005 Dec; 32(12): 2405-9.
 61. Reginster JY, Adami S, Lakatos P, Greenwald M, Stepan JJ, Silverman SL, et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2-year results from the MOBILE study. *Ann Rheum Dis*. 2006 May; 65(5): 654-61. Erratum in: *Ann Rheum Dis*. 2008 Feb; 67(2): 280.
 62. Cramer JA, Silverman SL. Persistence with bisphosphonate treatment for osteoporosis: finding the root of the problem. *Am J Med* 2006 Apr; 119(4 Suppl1): S12-7.
 63. Silverman SL. Lessons from osteoporosis clinical trials. *Alzheimers Dement*. 2006 Jul; 2(3): 155-9.
 64. Zingmond DS, Soohoo NF, Silverman SL. The role of socioeconomic status on hip fracture. *Osteoporos Int*. 2006 Oct; 17(10): 1562-8.
 65. Silverman SL, Watts NB, Delmas PD, Lange JL, Lindsay R. Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: The risedronate and alendronate (REAL) cohort study. *Osteoporos Int* 2007; 18:25-34.
 66. Silverman SL, Shen W, Minshall M, Xie S, Moses K. Prevalence of depressive symptoms in postmenopausal women with low bone mass and/or prevalent vertebral fractures: Results from the Multiple Outcomes of Raloxifene (MORE) Study. *J Rheumatol*. 2007 Jan; 34(1): 140-4.
 67. Silverman SL. Selecting patients for osteoporosis therapy. *Ann N Y Acad Sci*. 2007 Nov; 1117: 264-72.
 68. Cramer JA, Silverman SL, Gold DT. Methodological considerations in using claim databases to evaluate persistence with bisphosphonates for osteoporosis. *Curr Med Res Opin*. 2007 Oct; 23(10): 2369-77.
 69. Khosla S, Burr D, Cauley J, Silverman SL, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. *J Bone Miner Res*. 2007 Oct; 22(10): 1479-91.
 70. Silverman SL, Gold DT, Cramer JA. Reduced fracture rates observed only in patients with proper persistence and compliance with bisphosphonate therapies. *South Med J*. 2007 Dec; 100(12): 1214-8.
 71. Silverman SL, Cummings SR, Watts NB; Consensus Panel of the ASBMR, ISCD, and NOF. Recommendations for the clinical evaluation of agents for treatment of osteoporosis: consensus of an expert panel representing the ASBMR, ISCD, and NOF. *J Bone Miner Res*. 2008 Jan; 23(1): 159-65.
 72. Lewiecki EM, Baim S, Binkley N, Bilezikian JP, Kendler DL, Hans DB, Silverman SL. Report of the International Society for Clinical Densitometry 2007 Adult Position Development Conference and Official Positions. *South Med J*. 2008 Jul; 101(7): 735-739.
 73. Lewiecki EM, Gordon CM, Baim S, Binkley N, Bilezikian JP, Kendler DL, Hans DB, Silverman SL, et al. Special Report on the 2007 Adult and

- Pediatric Position Development Conferences of the International Society for Clinical Densitometry. *Osteoporos Int.* 2008 Oct; 19(10): 1369-78.
74. Silverman SL. Paget Disease of Bone: Therapeutic Options. *J Clin Rheumatol.* 2008 Oct; 14(5): 299-305.
 75. Lewiecki EM, Gordon CM, Baim S, Leonard MB, Bishop NJ, Bianchi ML, Kalkwarf HJ, Langman, CB, Plotkin H, Rauch F, Zemel BS, Binkley N, Bilezikian JP, Kendler DL, Hans DB, Silverman S. International society for clinical densitometry 2007 adult and pediatric official positions. *Bone.* 2008 Dec; 43(6): 1115-21.
 76. Silverman SL, Christiansen C, Genant HK et al. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo, and active-controlled clinical trial. *J Bone Miner Res.* 2008 Dec; 23(12): 1923-34.
 77. Cranney A, Wells GA, Yetisir E, Adami S, Cooper C, Delmas PD, Miller PD, Papapoulos S, Reginster JY, Sambrook PN, Silverman S, Siris E, Adachi JD. Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data. *Osteoporos Int.* 2008 Jul 29.
 78. ASBMR Task Force on Osteonecrosis of the Jaw, Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, Gagel RF, Gilsanz V, Guise T, Koka S, McCauley LK, McGowan J, McKee MD, Mohla S, Pendrys DG, Raisz LG, Ruggiero SL, Shafer DM, Shum L, Silverman SL, Van Poznak CH, Watts N, Woo SB, Shane E. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. *J Oral Maxillofac Surg.* 2008 Jun; 66(6): 1320-1; author reply 1321-2. No abstract available. Erratum in: *J Oral Maxillofac Surg.* 2008 Aug; 66(8): 1778.
 79. Baim S, Binkley N, Bilezikian JP, Kendler DL, Hans DB, Lewiecki EM, Silverman S. Official Positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Position Development Conference. *J Clin Densitom.* 2008 Jan-Mar; 11(1): 75-91.
 80. Chestnut CH 3rd, Azria M, Silverman S, et al. Salmon calcitonin: a review of current and future therapeutic indications. *Osteoporos Int.* 2008 Apr; 19(4): 479-91.
 81. Blumentals WA, Harris ST, Cole RE, Huang L, Silverman SL. Risk of Severe Gastrointestinal Events in Women Treated with Monthly Ibandronate or Weekly Bisphosphonates: A retrospective Database Study. *Ann Pharm.* 2009 Apr; 43(4): 577-85.
 82. Binkley N, Martens MG, Silverman SL, Derman RJ, Greenwald M, Kohles JD, Bachman GA. Improved GI Tolerability with Monthly Ibandronate in Women Previously Using Weekly Bisphosphonates. *South Med J.* 2009 May; 102(5): 486-92.
 83. Silverman SL. From randomized controlled trials to observational studies. *Am J Med.* 2009 Feb; 122(2): 114-20.
 84. Bonnick SL, Silverman SL, Tanner SB, Martens M, Bachman G, Civitelli R, Kohles, JD. Patient satisfaction in postmenopausal women treated with a weekly bisphosphonate transitioned to once monthly ibandronate. *J Womens Health (Larchmt).* 2009 Jun 29.
 85. Silverman SL, Landesberg R. Osteonecrosis of the jaw and the role of

- bisphosphonates: A critical review. *Am J Med* 2009 Feb; 122: S33-S45.
86. Silverman SL, Dukes EM, Johnston SS, Brandenburg NA, Sadosky A, Huse DM. The economic burden of fibromyalgia: comparative analysis with rheumatoid arthritis. *Curr Med Res Opin.* 2009 Apr; 25(4): 829-40.
 87. Siris ES, Selby PL, Saag KG, Borgstrom F, Herings R, Silverman SL. Impact of Osteoporosis Treatment Adherence on Fracture Rates in North America and Europe. *Am J Med.* 2009 Feb; 122: S3-13.
 88. Russel IJ, Perkins AT, Michalek JE, Bennett RM, Price M, Barron A, Evans T, Diab I, Lacombe J, Habros JS, Yatabe H, Holman AJ, Meyers R, Kivitz A, Morrison D, Kopp E, Downs J, Mease P, Granner D, Neiman A, Fanguy D, Nordstrom D, Sturgeon R, Pappas J, Wilkinson J, Patkar A, Tarter K, Haynes W, Seiden D, Rosen F, Sheldon EA, Alabaci M, Silverman SL, et al. Sodium Oxybate Relieves Pain and Improves Function in Fibromyalgia Syndrome: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial. *Arthritis and Rheumatism* 2009. Volume 60, Issue 1, pp. 299-309.
 89. Harris ST, Reginster JY, Harley C, Blumentals WA, Poston SA, Barr CE, Silverman SL. Risk of fracture in women treated with monthly oral ibandronate or weekly bisphosphonates: the evaluation of ibandronate efficacy (VIBE) database fracture study. *Bone.* 2009 May; 44(5): 758-65.
 90. Binkley N, Silverman SL, Simonelli C, et al. Monthly ibandronate suppresses serum CTX-I within 3 days and maintains a monthly fluctuating pattern of suppression. *Osteoporos Int.* 2009 Sep; 20(9): 1595-601.
 91. Kleinman N, Harnett J, Melkonian A, Lynch W, Kaplan-Machlis B, Silverman SL. Burden of fibromyalgia and comparisons with osteoarthritis in the workforce. *J Occup Environ Med.* 2009 Dec; 51(12):1384-93.
 92. Hooven FH, Adachi JD, Adami S, Boonen S, Compston J, Cooper C, Delmas P, Diez-Perez A, Gehlbach S, Greenspan SL, LaCroix A, Lindsay R, Netelenbos JC, Pfeilschifter J, Roux C, Saag KG, Sambrook PN, Silverman SL, et al. The Global Longitudinal Study of Osteoporosis in Women (GLOW): rationale and study design. *Osteoporos Int.* 2009; 20(7): 1107-16.
 93. As a member of the Fibromyalgia Working Group, Mease P, Arnold LM, Choy EH, et al. Fibromyalgia Syndrome module at OMERACT 9: domain construct. *J Rheumatol.* 2009 Oct; 36(10): 2318-29.
 94. Silverman SL, Harnett J, Zlateva G, Mardekian J. Identifying Fibromyalgia-Associated Symptoms and Conditions from a Clinical Perspective: A Step Toward Evaluating Healthcare Resource Utilization in Fibromyalgia. *Pain Pract.* 2010 Nov-Dec; 10(6): 520-9.
 95. Silverman SL, Gold DT. Compliance and Persistence with Osteoporosis Medications: A Critical Review of the Literature. *Rev Endocr Metab Disord.* 2010 Dec; 11(4): 275-80.
 96. Adachi JD, Adami S, Gehlbach S, Anderson FA, Boonen S, Chapurlat RD, Compston JE, Cooper C, Delmas P, Diez-Perez A, Greenspan SL, Hooven FH, LaCroix AZ, Lindsay R, Netelenbos JC, Wu O, Pfeilschifter J, Roux C, Saag KG, Sambrook PN, Silverman SL, et al. Impact of Prevalent Fractures

- on Quality of Life: Baseline results from the Global Longitudinal Study of Osteoporosis in Women. *Mayo Clin Proc.* 2010; 85(9): 806-13.
97. Bonnick SL, Harris ST, Kendler DL, McClung MR, Silverman SL. Management of Osteoporosis in Postmenopausal Women: 2010 Position Statement of the North American Menopause Society. *NAMS 2010.* 17(1): 25-54.
 98. Silverman SL, Schousboe JT, Gold DT. Oral bisphosphonate compliance and persistence: a matter of choice. *Osteoporos Int.* 2010 May 11.
 99. Silverman SL, Sadosky A, Evans C, et al. Toward Characterization and Definition of Fibromyalgia Severity. *BMC Musculoskelet Disord.* 2010 Apr 8; 11:66.
 100. Lafleur J, McAdam-Marx C, Alder SS, Sheng X, Asche CV, Nebeker J, Brixner DI, Silverman SL. Clinical risk factors for fracture among postmenopausal patients at risk for fracture: a historical cohort study using electronic medical record data. *J Bone Miner Metab.* 2010 Aug 6.
 101. Hochberg MC, Silverman SL, Barr CE, Miller PD. The utility of changes in serum levels of C-terminal telopeptide of type I collagen in predicting patient response to oral monthly ibandronate therapy. *J Clin Densitom.* 2010 Apr-Jun; 13(2): 181-9.
 102. Sambrook PN, Silverman SL, Cauley JA, et al. Health-related quality of life and treatment of postmenopausal osteoporosis: Results from the HORIZON-PFT. *Bone.* 2011 Mar 21.
 103. Harnett J, Margolis J, Cao Z, Fowler R, Sanchez RJ, Mardekian J, Silverman SL. Real-World Evaluation of Health-Care Resource Utilization and Costs in employees with Fibromyalgia Treated with Pregabalin or Duloxetine. *Pain Pract.* 2010 Dec 28.
 104. Silverman SL. Osteoporosis therapies: evidence from health-care databases and observational population studies. *Calcif Tissue Int.* 2010 Nov; 87(5): 375-84.
 105. LaFleur J, McAdam-Marx C, Alder SS, Sheng X, Asche CV, Nebeker J, Brixner DI, Silverman SL. Clinical risk factors for fracture among postmenopausal patients at risk for fracture: a historical cohort study using electronic medical records data. *J Bone Miner Metab.* 2011 Mar; 29(2): 193-200.
 106. Adachi JD, Adami S, Gehlbach S, Anderson FA Jr, Boonen S, Chapurlat RD, Compston JE, Cooper C, Delmas P, Diez-Perez A, Greenspan SL, Hooven FH, LaCroix AZ, Lindsay R, Netelenbos JC, Wu O, Pfeilschifter J, Roux C, Saag KG, Sambrook PN, Silverman S, et al. Impact of prevalent fractures on quality of life: baseline results from the global longitudinal study of osteoporosis in women. *Mayo Clin Proc.* 2010 Sep; 85(9): 806-13.
 107. Silverman SL, Harnett J, Zlateva G, Mardekian J. Identifying fibromyalgia-associated symptoms and conditions from a clinical perspective: a step toward evaluating healthcare resource utilization in fibromyalgia. *Pain Pract.* 2010 Nov-Dec; 10(6): 520-9.
 108. Margolis J, Cao Z, Fowler R, Harnett J, Sanchez RJ, Mardekian J, Silverman SL. Evaluation of healthcare resource utilization and costs in employees with painful diabetic peripheral neuropathy treated with

- pregabalin or duloxetine. *J Med Econ.* 2010; 13(4): 738-47. Silverman SL, Gold DT. Healthy users, healthy adherers, and healthy behaviors? *J Bone Miner Res.* 2011 Apr; 26(4): 681-2.
109. Cauley JA, El-HajjFuleihan G, Arabi A, Fujiwara S, Ragi-Eis S, Calderon A, Chionh SB, Chen Z, Curtis JR, Danielson ME, Hanley DA, Kroger H, Kung AW, Lesnyak O, Nieves J, Pluskiewicz W, El Rassi R, Silverman S, et al. Official Positions for FRAX Clinical Regarding International Differences from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX. *J Clin Densitom.* 2011 Jul-Sep; 14(3): 240-62.
 110. Siris ES, Gehlbach S, Adachi JD, Boonen S, Chapurlat R, Compston J, Cooper C, Delmas P, Diez-Perez A, Hooven FH, LaCroix A, Netelenbos JC, Pfeilschifter J, Rossini M, Roux C, Saag KG, Sambrook P, Silverman SL, et al. Failure to perceive increased risk of fracture in women 55 years and older. The Global Longitudinal Study of Osteoporosis in Women (GLOW). *Osteoporosis Int.* 2011; 22(1): 27-35.
 111. Nasser KM, Focil A, Silverman SL. Comparison of FRAX Scores of Southern California Females of Mexican Descent Using US Hispanic and Mexico Database. *J Osteoporos.* 2011; 2011:531359.
 112. Mease PJ, Clauw DJ, Christensen R, Crofford LJ, Gendreau RM, Martin SA, Simon LS, Strand V, Williams DA, Arnold LM; Silverman SL as part of the OMERACT Fibromyalgia Working Group. Toward development of a fibromyalgia responder index and disease activity score: OMERACT module update. *J Rheumatol.* 2011 Jul; 38(7): 1487-95.
 113. Marsh D, Akesson K, Beaton DE, Bogoch ER, Boonen S, Brandi ML, McLellan AR, Mitchell PJ, Sale JE, Wahl DA; Silverman SL as part of the IOF CSA Fracture Working Group. Coordinator-based systems for secondary prevention in fragility fracture patients. *Osteoporos Int.* 2011 Jul; 22(7): 2051-65.
 114. Diez-Perez A, Hooven FH, Adachi JD, Adami S, Anderson FA, Boonen S, Chapurlat R, Compston JE, Cooper C, Delmas P, Greenspan SL, Lacroix AZ, Lindsay R, Netelenbos JC, Pfeilschifter J, Roux C, Saag KG, Sambrook P, Silverman S, et al. Regional differences in treatment for osteoporosis. The Global Longitudinal Study of Osteoporosis in Women (GLOW). *Bone.* 2011 Sep; 49(3): 493-8.
 115. Cauley JA, Black D, Boonen S, Cummings SR, Mesenbrink P, Palermo L, Man Z, Hadji P, Reid IR; Silverman SL as part of the HORIZON Pivotal Fracture Group. Once-yearly zoledronic acid and days of disability, bed rest, and back pain: randomized, controlled HORIZON Pivotal Fracture Trial. *J Bone Miner Res.* 2011 May; 26(5): 984-92.
 116. Brown TM, Garg S, Chandran AB, McNett M, Silverman SL, Hadker N. The impact of 'best-practice' patient care in fibromyalgia on practice economics. *J Eval Clin Pract.* 2011 May 3.
 117. Sambrook PN, Silverman SL, Cauley JA, Recknor C, Olson M, Su G, Boonen S, Black D, Adachi JD; HORIZON Pivotal Fracture Trial. Health-related quality of life and treatment of postmenopausal osteoporosis; results from the HORIZON-PFT. *Bone.* 2011 Jun 1; 48(6): 1298-304.

118. Silverman SL, Chines AA, Kendler DL, Kung AW, Teglbjaerg CS, Felsenberg D, Mairon N, Constantine GD, Adachi JD. Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study. *Osteoporos Int*. 2011 Jul 21. Epub ahead of print. (OA)

**Research
Papers (Peer
Reviewed / In
Press)**

1. Garg S, Chandran AB, Kim D, Silverman S, McNett M. The impact of “best practice” patient care in fibromyalgia on practice economics. *Journal of Evaluation in Clinical Practice*. In Press.
2. Nasser K, Focil A, Silverman S. Comparison of FRAX scores of Southern California females of Mexican descent using US Hispanic and Mexico database. *Journal of Osteoporosis*. In Press.
3. Compston JE, Watts NB, Chapurlat R, Cooper C, Boonen S, Greenspan S, Pfeilschifter J, Silverman S, et al. Obesity is not protective against fracture and increases the risk of lower leg fractures in postmenopausal women: The Global Longitudinal study of Osteoporosis in Women (GLOW). *Am J Med* 2011. In Press.
4. Diez-Perez A, Hooven FH, Adachi JD, Adami S, Anderson FA, Boonen S, Chapurlat R, Compston JE, Cooper C, Delmas P, Greenspan SL, LaCroix AZ, Lindsay R, Netelenbos JC, Pfeilschifter J, Roux C, Saag KG, Sambrook P, Silverman S, et al. Regional differences in treatment for osteoporosis. The Global Longitudinal study of Osteoporosis in Women (GLOW). *Bone* 2011. In Press.

RESEARCH PAPERS (NON-PEER REVIEWED) - CHAPTERS, LETTERS, REVIEWS, EDITORIALS, PAPERS IN PREPARATION, ABSTRACTS

Chapters

1. Silverman SL. “Calcitonin” in *The Osteoporotic Syndrome*, L Avioli, Ed. Academic Press, 2000. Pp 133-144.
2. Silverman SL. “Calcitonin” in *Osteoporosis: Prevention, Diagnosis and Management*. American College of Physicians. F. Cosman and S. Cummings Eds. 2000.
3. Silverman SL. “Calcitonin” in *Osteoporosis*, S. Cummings, Felicia Cosman and S. Jamal, ed. 2002. ACP, Pp 197-208.
4. Silverman SL, Martin S. “Assessment Tools and Outcome Measures Used in the Investigation of Fibromyalgia” in *Fibromyalgia and Other Central Pain Syndromes*, Eds. DJ Wallace, DJ Clauw. 2005 Lippincott Williams and Wilkins, pp.309-320.
5. Silverman SL. “Calcitonin” in Maricic M, Gluck O Eds. *Metabolic Bone Disease in Rheumatology*. 2005.
6. Silverman SL. “Calcitonin” in Lane N and Sambrook P. *Osteoporosis and Osteoporosis of Rheumatic Diseases*. 2006.
7. Gold DT, Silverman SL. Adverse Health Outcomes in Men with Osteoporosis. In: E Orwoll, JP Bilezikian, and D Vanderschueren, Editors,

- Osteoporosis in Men. 2nd edition. Elsevier, San Diego, CA. 2009.
8. Gold DT, Silverman SL. "Quality of Life in Men with Osteoporosis." Orwoll E, Bilezikian J, Vanderschueren. Osteoporosis in Men: The Effects of Gender on Skeletal Health. 2009.

Letters to the Editor

1. Silverman SL. Methodology questioned. J Am Dent Assoc. 2008 May; 139(5): 537-8.
2. Silverman SL, Ott SM, Dell RM. Bisphosphonates and atypical femoral fractures. N Engl J Med. 2010 Sep 9; 363(11):1083; author reply 1084-5. No abstract available.

Reviews

1. Silverman SL. Calcitonin. Rheum Dis Clin North Am. 2001 Feb; 27(1): 187-96.
2. Silverman SL. "Calcitonin" in Geriatric Clinics of North America, E. Siris, ed. 2002.
3. Silverman SL. Calcitonin in Endocrine Clinics of North America, J. Bilzekian, ed. 2003. 32 (1):273-284.
4. Silverman SL, Azria M. The analgesic role of calcitonin following osteoporotic fracture. Osteoporos Int. 2002 Nov; 13(11): 858-67.
5. Silverman, SL. Calcitonin. Endocrinol Metab Clin North Am. 2003 Mar; 32(1): 273-84.
6. Silverman SL, Chesnut CH. Calcitonin Therapy for Osteoporosis. The Primer on Metabolic Bone Disease, Chapter 56.
7. Silverman SL. Quality-of-Life Issues in Osteoporosis. Curr Rheumatol Rep. 2005 Mar; 7(1): 39-45.
8. Lewiecki EM, Silverman SL. Redefining osteoporosis treatment: Who to treat and how long to treat. Arq Bras Endocrinol Metabol. 2006 Aug; 50(4): 694-704.
9. Gold DT, Silverman SL. Review of Adherence to Medications for the treatment of osteoporosis. Curr Osteoporos Rep 2006 Mar; 4(1): 21-7.
10. Silverman SL. Who should we treat with osteoporosis medication? Future Rheumatology 2006.
11. Silverman SL. Monitoring therapies in Osteoporosis. Menopause Management 2006.
12. Silverman SL. Compliance to osteoporosis medications. Clin In Rheum Diseases. 2006.
13. Silverman SL. Selecting patients for osteoporosis therapy. Current Osteoporosis Report 2006 Sep; 4(3): 91-5.
14. Silverman SL. Adherence to osteoporosis therapies. US Musculoskel Dis 2006.
15. Silverman SL. Adherence to medications for the treatment of osteoporosis. Rheum Dis Clin North Am. 2006 Nov; 32(4): 721-31.
16. Cramer JA, Silverman SL. Persistence with bisphosphonate treatment for osteoporosis: finding the root of the problem. Am J Med. 2006 Apr; 119(4 Suppl 1): S12-7.
17. Silverman SL. Managing fibromyalgia: the role of pharmacologic and

- nonpharmacologic therapies. National Fibromyalgia Association of the United Kingdom. 2007.
18. Gold DT, Silverman SL. Estrogen and SERMs: What is their impact on HRQOL? Current Osteoporosis Report 2007.
 19. Silverman S, Cramer J, Gold D. Overall persistence with bisphosphonate therapies using multiple databases. Osteoporosis Int 2007.
 20. Silverman SL. Calcitonin. US Endocrin Dis 2007.
 21. Gold DT, Silverman SL. Review of adherence to medications for treatment of osteoporosis. Current Prim Care Reports. 2007.
 22. Gold DT, Silverman SL. Do estrogen or selective estrogen receptor modulators improve quality of life for women with postmenopausal osteoporosis? Curr Osteoporos Rep. 2007 Mar; 5(1): 3-7.
 23. Silverman SL, Maricic M. Recent developments in bisphosphonate therapy. Semin Arthritis Rheum. 2007 Aug; 37(1): 1-12.

Editorials

1. Gold DT, Silverman SL. Compliance and persistence with osteoporosis therapies: We can do better. Future Rheum. 2007 Aug. In Editorial.
2. Silverman SL, Gold DT. Healthy users, healthy adheres, and healthy behaviors? J Bone Miner Res. 2011 Apr; 26(4): 681-2.

Abstracts

1. Brandli, D., Goldenhersh, M., Hahn, T., Greenwald, M., Golde, G., & Silverman, S.L., "Growth Hormone Treatment of Glucocorticoid-Induced Osteoporosis," Clin. Res. 39(1):115A, 1991.
2. Silverman, S.L., & Wallace, D., "Calcitonin Helps a Subset of Patients with Fibromyalgia," Arthritis and Rheumatism. 34(suppl):R21 abst 30W, 1991.
3. Mason, J.H., Silverman, S.L., Weaver, A., & Simms, R., "The Functional Impact of Fibromyalgia: a Comparison to RA," Arthritis Care Res. 4:523, 1991.
4. Silverman, S.L., Gallagher, J.C., Healey, J., Chesnut, C., & Baylink, D., A Multicenter Study of the Treatment of Steroid-Induced Osteoporosis with Injectable Calcitonin," Boston 1991.
5. Silverman, S.L., Brandli, D., & Greenwald, M., "Changes in Health Related Quality of Life During Osteoporosis Treatment," J. Bone Min Res, S177, abs 339, 1992.
6. Simms R., Mason J, Silverman S. "The Fibromyalgia Impact Assessment (FIA)," Presented 1992, International Conference on Myofascial Pain and Fibromyalgia, Copenhagen.
7. Evenson, M., Anderle D., Silverman S., "Learned Helplessness and Self-Efficacy - a Team Approach," Abst c288, Presented AHPA, Oct 1992.
8. Silverman S., Mason J. "Measurement of Pain in Fibromyalgia," presented at Borie Symposium, Los Angeles, California. November 1992.
9. Silverman S., Mason JH, Greenwald M., "The Osteoporosis Assessment Questionnaire (OPAQ): A Multidimensional Measure of Health Related Quality of Life in Osteoporosis," presented at the Fourth International Symposium on Osteoporosis, March 1993.
10. Silverman, S.L., Anderle-Johnson, D., "Prescription Medication Use in Fibromyalgia Patients," Arthritis Rheum 36,S5: R11 (Abs) 35,1993.

11. Silverman, S.L., Mason J., Greenwald, M., "The Osteoporosis Assessment Questionnaire (OPAQ): A Reliable and Valid Self Assessment Measure of Qual of Life in Osteoporosis, *Journal of Bone and Mineral Research*. 8(Suppl 1): s343 (abs 904).
12. Silverman, S.L., Greenwald, M., Golde, G., "Frequency of Nonresponders to Etidronate Therapy," *Journal of Bone and Mineral Research*. 8(Suppl 1): s342 (abs 901).
13. Silverman, S.L., Mason J., Greenwald, M., "Quality of Life after Osteoporotic Vertebral Fracture," *Arth Rheum* 1993.
14. Silverman, S.L., Greenwald, M., Golde, G., "Do Some Patients Lose Bone Despite Etidronate Therapy?" *Arth Rheum* 1993.
15. Silverman, S.L., Belza, B., Mason, J., Nakasone, R., "Measurement of Fatigue in Patients with Fibromyalgia as Compared to Rheumatoid Arthritis," *Arth Rheum* 1993.
16. Prange, B., Silverman, S.L., "Treating Injured Workers with Fibromyalgia: A Team Approach," Presented at the Southern California Arthritis Health Professions Meeting in Pasadena, California, April 9, 1994.
17. Silverman, S.L., Drinkwater, B., "Impact of Bone Density Information on the Decision to take Estrogen Therapy," *Clinical Research* 1994.
18. Baholydin, T., Silverman, S.L., Bormel, J., " Incidence of Hip Fracture in Ethnic Americans: The California Discharge Database," *Arth Rheum*, Vol 37, No. 9 (Supplement) September 1994, S301.
19. Silver, D., Silverman, S.L., Mendoza, M., "Chest Wall Syndrome in Patients Silicone Breast Implants," *Arth Rheum*, Vol 37, No. 9 (Supplement) September 1994, S270.
20. Silverman, S.L., Mendoza, M., Silver, D., Belza, B., "Measurement of Fatigue in Patients with Silicone Breast Implants (SBI) as Compared to Fibromyalgia (FM) and Rheumatoid Arthritis (RA)," *Arth Rheum*, Vol. 37, No. 9 (Supplement) September 1994, S271.
21. McClung, M., Bensen, W., Bolognese, M., Bonnicksen, S., Ettinger, M., Harris, S., Heath, H., Lang, R., Miller, P., Pavlov, E., Silverman, S.L., Woodson, G., Faulkner, K., Bekker, P., "Risedronate Treatment of Postmenopausal Women with Low Bone Mass: Preliminary data." Presented at 1996 World Conference of Osteoporosis in Amsterdam, Holland.
22. Silverman, S.L., Go K., Tou, K., "What is the Quality of Life of Patients with Osteoporosis?" Accepted for presentation at the ASBMR, Seattle Washington. September 9, 1996.
23. Baholyodin, T., Philley, F., Bormel, J., Schneider, D.L., Silverman, S.L., "Decreasing Secular Trends in the Incidence of Hip Fracture in Women in California: 1983-1992", Presented at the ASBMR, Seattle, Washington. September 9, 1996.
24. Notelovitz, M., Rebar, R., Speroff, L., Block, M., Greenwald, M., Silverman, S.L., Yang, H.M., Nolan, J.C. "Low Dose Esterified Estrogens: Prevention of Postmenopausal Bone Loss without Development of Endometrial Hyperplasia." Presented at the North American Menopause Society, 1996.
25. Greenwald, M., Silverman, S. "Barriers to Osteoporosis Care". Accepted for presentation at the ACR, Orlando, Florida. October 1996.
26. Silverman, S., Tou, K., Go, K., Quality of Life in Patients with Osteoporosis

- and Osteopenia". ACR, Orlando, Florida. October 1996.
27. Silverman, S., Borenstein, D., Solomon, G., Espinoza, L., Collins, M., "Preliminary Operational Criteria for Systemic Silicone Related Disease (SSRD). Presented at the ACR, Orlando, Florida. October 1996.
 28. Goldsmith, D., Silverman, S., Solomon, G., "Estimates for Sensitivity and Specificity for Diagnosis of Systemic Silicone Related Disorder (SSRD) by Experienced Practitioners". Presented at the ACR, Orlando, Florida. October 1996.
 29. Silverman, S., Go, K. "Correlation of Quality of Life in Osteoporosis to Clinical Endpoints", Western Region ACR meeting, San Diego, CA. March 1997.
 30. McClung, M., Bensen, W., Bolognese, M., Bonnicksen, S., Ettinger, M., Harris, S., Heath, H., Lang, R., Miller, D., Pavlov, E., Silverman, S., Woodson, G., Faulkner, K., Bekker, P., Axelrod, D. "Risedronate Increased BMD at the Hip and Spine in Postmenopausal Women with Low Bone Mass". ASBMR 1997.
 31. Bekker, P., McClung, M., Bensen, W., Bolognese, M., Bonnicksen, S., Ettinger, M., Harris, S., Heath, H., Lang, R., Miller, P., Pavlov, e., Silverman, S., Woodson, G., Faulkner, K., Axelrod, D. "Risedronate is Effective in Increasing BMD in Both Early and Late Postmenopausal Women with Low Bone Mass." J Bone Min Res 1997. 12(S1): S471 (Abs. S474).
 32. Silverman, S., Go, K. "Correlation of Quality of Life in Osteoporosis to Clinical Endpoints. ILAR conference in Singapore, June 1997.
 33. Silverman, S.L., Minshall, M., "Relative Importance of Functional State, Comorbid Illness, and Age on Overall Health Related Quality of Life in Patients with Osteoporotic Vertebral Fracture(s)". J Bone Min res 1997. 12(S1), S364 (Abs. F554).
 34. Silverman, S.L., Minshall, M., "Principal Component Factor Analysis of Quality of Life in Patients with Osteoporotic Vertebral fracture(s)". J Bone Min res 1997. 12(S1), S364 (Abs. F553).
 35. Silverman, S.L., Go, K., Herson, J. "What is the Relative Impact of Osteoporotic Vertebral fracture as Compared to Aging on Quality of Life?", J Bone Min res 1997. 12(S1), S363 (Abs. F549).
 36. Greenwald, M., Silverman, S.L., "Sensitivity and Specificity of P-DEXA Compared to Central DEXA in 284 Women". Bone Min res 1997. 12(S1), S259 (Abs. T632). Stock, L. Avioli, L.V., Baylink, D.J., Chesnut, C., Genant, H.J., Maricic, M.J., 3737.
 37. Silverman, S.L., Schaffer, A.V., Feinblatt, J., "Calcitonin-Salmon Nasal Spray Reduces the Incidence of New Vertebral Fractures in Postmenopausal Women: Three-Year Interim Results of the Proof Study". J Bone Min res 1997. 12(S1), S149 (Abs. 187)
 38. Silverman S.L., Go K., Herson J. (1997). What is the relative impact of osteoporotic vertebral fracture as compared to aging on quality of life? J Bone Min Res 12 (Suppl 1); S363.
 39. Silverman S.L., Minshall M.E., Shen W., Harper K., Kody M.C., Xie S. (1998). The association between selected risk factors and demographic variables on quality of life in established postmenopausal osteoporosis Osteoporosis Int 8:23.

40. Silverman S.L., Minshall M.E., Shen W., Harper K., Kody M.C., Xie S. The impact of a history of nonvertebral postmenopausal fracture on quality of life in established postmenopausal osteoporosis. *Osteoporosis Int* 1998 8:24.
41. Silverman S.L., Minshall M.E., Shen W., Harper K., Kody M.C., Xie S. (1998). The impact of vertebral fracture depends on the number and location of the fracture. *Bone* 1998 Abs T440, 423(5): S305.
42. Silverman S.L., Lips P., Minshall M.E., Oleksik A., Spritzer K. (1998). Does the impact of osteoporosis on health related quality of life differ between patients in the USA and the Netherlands? *Bone* 1998 Abs W339, 23(5): S398.
43. Chesnut C, Silverman SL, Andriano K, Genant H, Richardson P, Maricic M, Stock J, Baylink D, for the Proof Study Group. Salmon calcitonin nasal spray reduces the rate of new vertebral fractures independently of known major pretreatment risk factors. *Bone* 1998 Abs T373, 23(5):S290.
44. Silverman SL et al. Salmon calcitonin nasal spray reduced risk of vertebral fracture in established osteoporosis and has continuous efficacy with prolonged treatment: Accrued 5 year worldwide data of the PROOF study. *Bone* 1998 Abs 1108, 23(5): S174
45. Silverman SL, Simons R. Utility values for osteoporosis outcomes. *Bone* 1998 Abs W443. 23(5): S398
46. Maricic M, Silverman S, et al. Accrued analysis of the PROOF study. *Arth Rheum* 1998.
47. Hallegula D, Wallace D, Silverman S et al. Growth hormone deficiency and fibromyalgia. *Arth Rheum* 1998
48. Silverman SL, Chesnut C, Maricic MJ, Andriano K, Gimona A: Age and Lumbar Spine BMD Are the Strongest Predictors of Vertebral Fractures through Five years. *J Bone Min Res* 1999; 14 (Suppl 1); S 516 (abs SU337).
49. Silverman SL, Minshall ME, Shen W, Harper KD, Xie S: the Impact of Incident Vertebral Fracture on Health Related Quality of Life in Established Postmenopausal Osteoporosis: Results from the Multiple Outcomes of Raloxifene Evaluation Study. *J Bone Min Res* 1999; 14 (Suppl 1); S159 (abs1106).
50. Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J, Adami S, Weber K, Lorenc P, Pietschman P, Silverman SL: Alendronate Treatment of Osteoporosis in Men. *J Bone Min Res* 1999; 14 (Suppl 1); S184 (abs 1205).
51. Shen W, Silverman SL, Minshall ME, Harper KD, Xie S: Measuring Health Related Quality of Life in Postmenopausal Women with Osteoporosis: Development and Validation of a Short Version of the Osteoporosis Assessment Questionnaire. *J Bone Min Res* 1999; 14 (Suppl 1); S204 (abs T259).
52. Silverman SL, Minshall ME, Shen W, Harper KD, Xie S: The Association between Vertebral Fracture and Depression as Measured by the Affective Rating Scale (ARS): Results from the Multiple Outcomes of Raloxifene Evaluation (MORE) Study. *J Bone Min Res* 1999; 14 (Suppl 1); S261 (abs F261).

53. Silverman, SL, et al. Final Worldwide Analysis of the PROOF study. *Calcif. Tissue Int'l*, 1999. Vol. 64, Suppl.1, (S43).
54. Nattras S, Silverman S, Drinkwater B, Effectiveness of Education and/or NTx Results As a Means of Encouraging Compliance to Alendronate. Presented at WCO, Chicago, 2000.
55. D. Silver, L. Al-Dayeh, X. Bi, K. Hudson, S. Silverman, Standard X-ray with intensifying screens for radiographic absorptiometry: A pilot study. Presented at the World Congress on Osteoporosis in Chicago, June 15, 2000.
56. S.L. Silverman, S. Nattrass, B. Drinkwater. Compliance to osteoporosis therapy: Importance of DXA and relative unimportance of bone marker information. *J Bone Min Res* 2000; 15 (Suppl 1); S561 (abs M441)
57. S.L. Silverman, D. Gold, B. Miller, Choices Advisory Board, Alpha and Beta test of CHOICES for better bone health: An osteoporosis Self Management Course. *J Bone Min Res* 2000; 15 (Suppl 1); S561 (abs M442)
58. M. Greenwald, S.L. Silverman, E. Boling, D. Silver, X. Bi, L. Al-Dayeh, Precision of Radiographic Absorptiometry using standard x-ray technique, *J Bone Min Res* 2000; 15 (Suppl 1); S518 (abs M263)
59. E. Boling, M. greenwald, D. Silver, L. Al-Dayehm X. Bi, S.L. Silverman, Radiographic Absorptiometry: A precision study. *J Bone Min Res* 2000; 15 (Suppl 1); S519 (abs M266).
60. S. E. Tong, R. D. Wasnich, S.T. Harris, S.R. Weiss, M.A.Bolognese, S.B. Cohen, S.L. Silverman, J.C. Gallagher. Therapeutic effects in postmenopausal osteoporotic (PMOP) women of a vitamin D. analog. *J Bone Min Res* 2000; 15 (Suppl 1); S562 (abs M448).
61. W. Bensen, F. Piette, M. Ettinger, S. Horlait, O. Dimunno, S. Silverman, K. Bos, J. Reginster, Risedronate significantly reduces hip fracture risk in elderly women with osteoporosis. *J Bone Min Res* 2000; 15 (Suppl 1); S226 (abs F384).
62. M. Gamber, S.L. Silverman, The ethnophysiology of osteoporosis in Mexican Americans in Fort Worth. *J Bone Min Res* 2000; 15 (Suppl 1); S304 (abs SA370).
63. J. Adachi, S. Adami, P.Miller, W.P.Olszybski, D. kendler, S. Silverman, A. Licata, Z. Li, K. Stevens, P.H. Long, Risedronate is well tolerated in Alendronate-intolerant postmenopausal women. *J Bone Min Res* 2000; 15 (Suppl 1); S429 (abs SU401)
64. S.L. Silverman, K. Andriano, D. Baylink, C. Chesnut, M. Maricic, L. Mindeholm, PROOF study investigators, Monitoring of osteoporosis therapy with bone densitometry: Results from the PROOF study. *J Bone Min Res* 2000; 15 (Suppl 1); S433 (abs SU420)
65. SL Silverman, DT Gold, B Miller, Gamma Test of Choices for Better Bone Health *J Bone Min Res* 2001; 16 (Suppl 1); S541 (abs M465)
66. SL Silverman, C Chesnut, D Baylink, A Gimona, K Adriano, L Mindeholm, Salmon Calcitonin Nasal Spray (SCNS) is Effective and Safe in Older Osteoporotic Women – Results from the PROOF Study. *J Bone Min Res* 2001; 16 (Suppl 1); S530 (abs M414).
67. ME Minshall, SL Silverman, W Shen and S XIE, The Impact of Incident Vertebral and Non-vertebral Fractures on Health Related Quality of Life

- (HRQOL) in Established Post-Menopausal Osteoporosis: Results from the rh PTH (1-34) Randomized Placebo Controlled Trial in Post-Menopausal Women. *J Bone Min Res* 2001; 16 (Suppl 1); S541 (abs M462).
68. B Greenwald, A Bardwell, M Greenwald, J Malinak, R Rude, S. Silverman, DXA Report Influences Patient Compliance if Filling Prescriptions for Osteoporosis. *J Bone Min Res* 2001; 16 (Suppl 1); S336 (abs SU098).
 69. R Wasnich, L Al-Dayeh, X Bi, S Silverman: Absolute Fracture Risk Assessment From Phalangeal Bone Mineral Density Using Radiographic Absorptiometry. Presented at the 5th International Symposium on Clinical Advances in Osteoporosis. National Osteoporosis Foundation. March 2002
 69. Silverman, SL: Risedronate Is Well Tolerated In Osteoporotic Patients, Even Those over 80 Years of Age. Presented at The American College of Obstetricians and Gynecologists 50th Annual Clinical Meeting, Los Angeles, May 4-8, 2002.
 70. Silverman, SL, Kulkarni PM, Stock JL, Sarkar S, Wong M, Plouffe L. Comparison of fracture, cardiovascular, and breast cancer events at 3 years in placebo treated women with osteoporosis without prevalent fracture. Presented at the Endocrine Society meeting San Francisco 2002.
 71. Wasnich R, Al-Dayeh L, Bi X, Silverman S: Absolute Fracture Risk Assessment From Phalangeal Bone Mineral Density Using Radiographic Absorptiometry. Clinical Symposium on Clinical Advances in Osteoporodis. National Osteoporosis Foundation. March 2002. Honolulu.
 72. Greenwald K, Bardwell A, Kushner P, Malinak J, Lewiecki M, Rude R, Silverman S, and White-Greenwald M. Ultrasound Bone Density: Classification of Osteoporosis by Absolute Fracture Risk Improves Diagnosis and Treatment. To be presented at ACR Orlando Oct 2003
 73. Silverman SL, Zingmond D: Secular Trends in Hip Fractures Incidence in California 1983-2000 for Different Ethnic Groups. To be presented at ASBMR September 2003
 74. Silverman SL, Zingmond D: Racial and Ethnic Disparities in Length of Stay and Discharge Disposition of Patients with Hip Fracture. To be presented at ASBMR September 2003
 75. Olson M, Silverman SL, Mindeholm L, Azria M, Chestnut C: Discondances in Vertebral Fracture Reduction in Terms of Age and Fracture Location in Response to Calcitonin Nasal Spray: Results from the PROOF Study. To be presented at ASBMR September 2003.
 76. Silverman SL, Crans GG, Wong M, Stock JL, Genant HK. Relationships between age, number, and maximal severity of prevalent vertebral fractures with health related quality of life. 2003, *Osteoporos Int* 14(suppl 7): S49 (P198)
 77. Silverman SL, Crans GG, Wong M, et al. 2003 Relationships between age , number and maximal severity of prevalent vertebral fractures with health related quality of life. *Osteoporos Int*. 14(7):s49 (abs 198).
 78. Silverman SL, Piziak VK, Chen P, Krege JH, Wagman RB. Effect of new or worsening back pain on Health Related Quality of Life (HRQOL) in postmenopausal women with osteoporosis.

79. Silverman SL, Zingmond D: Increased Mortality Following Acute Hip Fracture: Secular Trends in California 1990 – 2001. *J Bone Min Res* 2004; abs 1187; vol 19 suppl1; pages S49.
80. Fang A, Abdelmalek A, Weisman M, Silverman SL: Diagnosis and Treatment of Osteoporosis in Vertebral Fracture Patients Who Have Undergone Vertebroplasty or Kyphoplasty: The Importance of Clinical Pathways. Presented at ASBMR 2004
81. Greenwald M, Al-Dayeh L, Bi X, Silverman SL: Radiographic Absorptiometry (RA) Assessment of Bone Mineral Density Using a CR-based System Compared to the Film-based System. Presented at ASBMR 2004
82. Miller PD, Silverman SL, Gold DT, Chen P, Taylor KA, Wagman RB: DANCE: Direct Analysis of Non-vertebral Fracture in the Community Experience Study Overview. Presented at ASBMR 2004
83. Silverman S, Siris E, Abbott T, Barr C, Harris S, Rosen C. Adherence to bisphosphonate Therapy is associated with decreased nonvertebral osteoporotic fracture risk. Accepted for ASBMR 2005
84. Silverman SL, Zingmond D. Socioeconomic Status is a significant predictor of hip fracture Rates 1996-2000. Accepted for ASBMR 2005
85. Silverman SL, Zingmond D. Men with hip fractures are younger, sicker and more likely to Die. Accepted for ASBMR 2005
86. Silverman SL, Miller P, Gold DT, Wagman RB. Rationale and evidence for initiating teriparatide therapy: interim results from DANCE. Accepted for ASBMR 2005.
87. Adami S, Bonvoisin B, Christiansen C, Cooper C, Delmas PD, Drezner MK, Emkey R, Felsenberg D, Greenwald M, Lakatos P, Mairon N, Miller PD, Reginster JY, Rowell L, Silverman SL, and Stepan JJ: Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2-year results from the MOBILE study *Ann Rheum Dis* Published Online First: 8 December 2005. doi:10.1136/ard.2005.044958
88. Barrera-Sierra S, Gaich C, Gold D, Silverman SL, Laster A, Chen P, Taylor K, Wagman R. Early Reduction in Back Pain: Interim Results from DANCE, Direct Assessment of Non-Vertebral Fracture in Community Experience. Submitted to ASBMR 2006.
89. Siris ES, Silverman SL, Harris ST, Barr CE. The relationship between adherence to bisphosphonate therapy and vertebral and non-vertebral fracture rates in osteoporotic women. Presented at IOF 2006
90. Silverman SL, Hochberg MC, Cole RE, Barr CE, Genant HK. Response to therapy with once-monthly ibandronate 150 mg: post-hoc analysis of BMD responders from the MOBILE study. Presented at IOF 2006
91. Gold DT, Weiss T, McHorney CA, Silverman SL. An Evaluation of Medication Convenience among Patients Taking Osteoporosis Medications: Results from the PREFER-US Study. Presented at IOF 2006.
92. Compston J, Silverman SL, Mathisen A, Gallwitz W. Parathyroid hormone (1-84) is effective in patients with a wide range of clinical risk factors. Presented at EULAR 2006.
93. Silverman SL, Miller P, Mathisen A, Gallwitz W. Effect of parathyroid hormone (1-84) in reducing new vertebral fractures regardless of

- baseline vertebral fracture status in patients with a wide range of clinical risk factors Submitted to ASBMR 2006.
94. Silverman SL, Miller P, Mathisen A, Gallwitz W. Parathyroid hormone (1-84) is effective in reducing new vertebral fractures in patients with a female family history of osteoporosis. ASBMR 2006.
 95. Silverman SL, Middelhoven H. Persistence on monthly vs weekly bisphosphonate therapy. Presented at ESPACOMP, November 30, 2006. Bonn Germany.
 96. S.L. Silverman, P.D. Miller, A. Mathisen, W. Gallwitz. Cedars-Sinai Medical Center, David Geffen School of Medicine, UCLA, Beverly Hills, CA, USA, Colorado Center for Bone Research, Lakewood, CO, USA, NPS Pharmaceuticals, INC, Parsippany, NJ, USA.
 97. P.D. Delmas, S.L. Silverman, N.B. Watts, J.L. Lange, R. Lindsay. INSERM Unit 403, Universie Vlaude Bernard Lyon 1, Lyon, France, Cedars-Sinai Medical Center, David Geffen School of Medicine, UCLA, Beverly Hills, CA, USA, Bone Health and Osteoporosis Center, University of Cincinnati, Cincinnati, OH, USA, P&G Pharmaceuticals, Mason, OH, USA, Helen Hayes Hospital, West Haverstraw, NY, USA.
 98. S. L. Bonnick, S. B. Tanner, M. Martens Civitelli, A. Kornowski, S. Silverman. Clinical Research Center of North Texas, Denton, TX, USA, Vanderbilt University, Nashville, TN, USA, University of Oklahoma, Tulsa, OK, USA, Washington University, St. Louis, MO, USA, Roche Laboratories, Nutley, NJ, USA, OMC Research, Beverly Hills, CA, USA.
 99. D. T. Gold, C. A. McHorney, T. W. Weiss, S. L. Silverman. Duke University Medical Center, Durham, NC, USA, Merck & Co., Inc., West Point, PA, USA, Outcomes Research, Merck & Co., Inc., West Point, PA, USA, Cedars-Sinai Medical Center UCLA, Beverly Hills, CA, USA.
 100. S. L. Silverman, C. H. Chesnut, M. M. Amonkar, J. Margolis, C. E. Barr. Cedars-Sinai/UCLA, Beverly Hills, CA, USA, Osteoporosis Research Group, University of Washington, Seattle, WA, USA, Roche Nutley, NJ, USA, Healthcore, Inc., Wilmington, CA, USA.
 101. C. Gaich, D. Gold, S. Silverman, A. Laster, P. Chen, K. Taylor, R. Wagman. Lilly Research Laboratories, Indianapolis, IN, USA, Duke University Medical Center, Durham, NC, USA, Osteo Medical Center, Beverly Hills, CA, USA, Arthritis and Osteo Consultants of the Carolinas, Charlotte, NC, USA.
 102. S. L. Silverman, A. Mathisen, W. Gallwitz. Cedars-Sinai Medical Center, David Geffen School of Medicine, UCLA, Beverly Hills, CA, USA, NPS Pharmaceuticals, Inc., Parsippany, NJ, USA.
 103. S. L. Silverman, T. W. Weiss, D. T. Gold, C. A. McHorney. Cedars-Sinai Medical Center, UCLA, Beverly Hills, CA, USA, Outcomes Research, Merck & Co., Inc., West Point, PA, USA, Duke University Medical Center, Durham, NC, USA.
 104. S. Silverman, R. Emkey, J. Y. Reginster, R. Lorenc, C. Hughes, D. Kendler. Cedars-Sinai Medical Center, Los Angeles, CA, USA, Radiant Research, Wyomissing, PA, USA, University of Liege, Liege, Belgium, The Children's Memorial Institute, Warsaw, Poland, F. Hoffman-La Roche Ltd., Basel, Switzerland, Osteoporosis Research Center, University of

- British Columbia, Vancouver, BC, Canada.
105. S. L. Silverman. Selecting patients for osteoporosis therapy: A new approach. *J Musculoskel Med.* 2007; 24: 207-211.
 106. S. L. Silverman, M. Maricic. Recent developments in Bisphosphonate Therapy. *Semin Arthritis Rheum* 37: 1-12.
 107. Shane E, Goldring S, Christakos S, Drezner M, Eisman J, Silverman S, Pendrys D. Osteonecrosis of the jaw: more research needed. *J Bone Miner Res.* 2006 Oct; 21(10): 1503-5.
 108. Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN, Abbott TA, Silverman SL. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. *Mayo Clin Proc.* 2006 Aug; 81(8): 1013-22.
 109. Weiss TW, Gold DT, Silverman SL, McHorney CA. An evaluation of patient preferences for osteoporosis medication attributes: results from the PREFER-US study. *Curr Med Res Opin.* 2006 May; 22(5): 949-60.
 110. Gold DT, Silverman SL. Review of adherence to medications for the treatment of osteoporosis. *Curr Osteoporos Rep.* 2006 Mar; 4(1): 21-7. Review.
 111. Silverman SL, Delmas PD, Kulkarni PM, Stock JL, Wong M, Plouffe L Jr. Comparison of fracture, cardiovascular event, and breast cancer rates at 3 years in postmenopausal women in osteoporosis. *J Am Geriatr Soc.* 2004 Sep; 52(9): 1543-8.
 112. Gold DT, Silverman SL. Osteoporosis self-management: Choices for Better Bone Health. *South Med J.* 2004 Jun; 97(6): 551-4.
 113. Oglesby AK, Minshall ME, Shen W, Xie S, Silverman SL. The impact of incident vertebral and nonvertebral fragility fractures on health-related quality of life in established postmenopausal osteoporosis: results from the teriparatide randomized, placebo-controlled trial in postmenopausal women. *J Rheumatol.* 2003 Jul; 30(7): 1579-83.
 114. Silverman SL, Cummings SR, Watts NB; For the Consensus Panel of the ASBMR, ISCD, and NOF. Recommendations for the Clinical Evaluation of Agents for Treatment of Osteoporosis: Consensus of an Expert Panel Representing the American Society for Bone and Mineral Research (ASBMR), the International Society for Clinical Densitometry (ISCD), and the National Osteoporosis Foundation (NOF). *J Bone Miner Res.* 2007 Sep 24.
 115. Cramer JA, Silverman SL, Gold DT. Methodological considerations in using claim databases to evaluate persistence with bisphosphonates for osteoporosis. *Curr Med Res Opin.* 2007 Aug 20.
 116. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, Gagel RF, Gilsanz V, Guise T, Koka S, McCauley LK, McGowan J, McKee MD, Mohla S, Pendrys DG, Raisz LG, Ruggiero SL, Shafer DM, Shum L, Silverman SL, Van Poznak CH, Watts N, Woo SB, Shane E. Bisphosphonate-Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research. *J Bone Miner Res.* 2007 Jul 30.

117. Silverman SL, Shen W, Minshall ME, Xie S, Moses KH. Prevalence of depressive symptoms in postmenopausal women with low bone mineral density and/or prevalent vertebral fracture: results from Multiple Outcomes of Raloxifene Evaluation (MORE) study. *J Rheumatol.* 2007 Jan; 34(1): 40-4.
118. Silverman SL. Reduced Fracture Rates Observed Only in Patients with Proper Persistence and Compliance with Bisphosphonate Therapies. *South Med Journal.* 2007. IN PRESS.
119. Watts NB, Greenspan SL, LaCroix A, Saag K, Silverman S, Siris E, Dedrick R, Lindsay R. Distribution of risk factors for fracture in women with or without a fracture history: a regional comparison. The Global Longitudinal Registry of Osteoporosis in Women. 17th Annual Meeting and Clinical Conference, American Association of Clinical Endocrinologists. Orlando FL, May 16, 2008, poster presentation. Abstract 504, Program Abstracts page 59.
120. Delmas P, Lindsay R, Boonen S, Cooper C, Hooven F, Silverman S, Roux C, Gehlbach S, Dedrick R, Anderson FA. Multinational comparison of bone health in women 55 years of age and older. The Global Longitudinal registry of Osteoporosis in Women. *Osteoporos Int* (2008) 19 (Suppl 1): S55.
121. Siris E, Diez-Perez A, Boonen S, Cooper C, LaCroix A, Watts NB, Saag KG, Silverman SL, et al. Failure to perceive increased risk of fracture in women 55+ years. The Global Longitudinal Study of Osteoporosis in Women. *JBMR* 2008; 23:S201.
122. Cooper C, Adachi JD, Anderson FA, Compston J, Netelenbos JC, Pfeilschifter J, Silverman SL, et al. Fragility fractures and health status in a multinational cohort. The Global Longitudinal Study of Osteoporosis in Women. *JBMR* 2008; 23:S327.
123. Delmas P, Adami S, Anderson FA, Gehlbach S, Pfeilschifter J, Sambrook P, Silverman SL, et al. Multinational comparison of bone health in women 55 years of age and older. The Global Longitudinal Study of Osteoporosis in Women. *JBMR* 2008; 23:S329.
124. Silverman SL, Adachi JD, Gehlbach S, et al. Risk factors for fragility fracture in a multiracial cohort of US women. The Global Longitudinal Study of Osteoporosis in Women. *JBMR* 2008; 23:S201.
125. Miller PD, Recker RR, Harris ST, Silverman SL, Felsenberg D, Barr CE, Day BM, Reginster JY. Long-term Fracture Efficacy with Continued Ibandronate Treatment: Pooled Analysis of DIVA and MOBILE Long-term Extension Studies. *ASBMR* September 2009.
126. Roux C, Adachi J, Compston J, Cooper C, Diez-Perez A, Greenspan SL, Netelenbos JC, Pfeilschifter J, Silverman SL, Nika G, Siris ES. Reasons for Stopping Anti-Osteoporosis Medications among Postmenopausal Women. The Global Longitudinal study of Osteoporosis in Women (GLOW). *ASBMR* September 2009.
127. Roux C, Boonen S, Adami S, Chapurlat R, Gehlbach S, Hooven F, Silverman SL, Siris ES, Watts NB, Nika G, Pfeilschifter J. Burden of Non-Hip-Non-Vertebral Fractures in Postmenopausal Women 55 Years and Older. The Global Longitudinal study of Osteoporosis in Women

- (GLOW). ASBMR September 2009.
128. Siris ES, Silverman SL, Viswanathan H, Qian Y, Ragi-Eis S, Fardellone P, Gilchrist N, Lips P, Nevitt M, Palacios S, Pavelka K, Revicki D, Simon J, Macarios D, Evaluation of Health-Related Quality of Life in Postmenopausal Women Who Participated in the FREEDOM Trial. ASBMR September 2009.
 129. Nguyen A, Solimeo S, Gold DT, Silverman SL. Reliability and Validity of Male OPAQ in Assessing QOL in Osteoporotic Males. ASBMR September 2009.
 130. Bilezikian J, Klemes A, Silverman SL, Cosman F. Subtrochanteric Fracture Reports Coincident with Risedronate Use. ASBMR September 2009.
 131. Silverman SL, Chines A, Zanchetta JR, Genant H, Kendler D, Rio de la Loza F, Kung A, Constantine GD, Adachi J. Sustained Efficacy of Bazedoxifene in Preventing Fractures in Postmenopausal Women with Osteoporosis: Results of a 5-Year , Randomized, Placebo-Controlled Study. ASBMR September 2009.
 132. Silverman SL, Zingmond D. Variability in Hispanic Hip Fracture Incidence Statewide in the US. ASBMR September 2009.
 133. Silverman SL, Miller PD, Recker RR, Felsenberg D, Dasic G, Barr CE, Day BM. Efficacy and Safety of Monthly Oral Ibandronate in Women Receiving Continuous Therapy for 5 Years. ACR 2009.
 134. Miller PD, Recker RR, Harris ST, Felsenberg D, Silverman SL, Dasic G, Day BM, Barr CE, Reginster JY. BMD Increases, Fracture Incidence and Safety after 5 Years of IV Ibandronate Injection Therapy in Women with Postmenopausal Osteoporosis. ACR 2009.
 135. Saag KG, LaCroix A, Silverman SL, et al. Past Fractures Increase Risk for Subsequent Fractures at Multiple Sites: Global Longitudinal Study of Osteoporosis in Women (GLOW). ACR 2009.
 136. Lindsay R, Silverman SL, Adachi JD, et al. Failure to perceive increased risk of fracture in women ≥ 55 years. The Global Longitudinal Study of Osteoporosis in Women. AGS 2009.
 137. Diez-Perez A, Adami S, Boonen S, Chapurlat R, Compston J, Cooper C, Roux C, Silverman SL, et al. Distribution of risk factors for fracture in women with and without a fracture history: a regional comparison. The Global Longitudinal Study of Osteoporosis in Women. ECCEO 2009.
 138. Silverman SL, Adachi JD, Adami S, et al. Risk factors for fragility fracture in a multiracial cohort of US women. The Global Longitudinal Study of Osteoporosis in Women. ECCEO 2009.
 139. Adami S, Boonen S, Cooper C, Diez-Perez A, Greenspan SL, LaCroix A, Saag KG, Silverman SL, et al. Failure to perceive increased risk of fracture in women aged 55 years and older. The Global Longitudinal Study of Osteoporosis in Women. ECTS 2009.
 140. Sambrook P, Adami S, Anderson FA, Gehlbach S, Pfeilschifter J, Silverman SL, et al. Multinational comparison of bone health in women 55 years of age and older. The Global Longitudinal Study of Osteoporosis in Women. IBMS 2009.
 141. Adachi JD, Compston J, Lindsay R, Saag KG, Silverman SL, et al.

- Distribution of risk factors for fracture in women with and without a fracture history: a regional comparison. The Global Longitudinal Study of Osteoporosis in Women. NOF 2009.
142. Compston J, Adachi JD, Lindsay R, Saag KG, Silverman SL, et al. Fragility fractures and health status in a multinational cohort. The Global Longitudinal Study of Osteoporosis in Women. NOF 2009.
 143. Lindsay R, Adachi JD, Compston J, Saag KG, Silverman SL, et al. Regional differences in the management of osteoporosis. The Global Longitudinal Study of Osteoporosis in Women. NOF 2009.
 144. Silverman SL, Adachi JD, Compston J, et al. Risk factors for fragility fracture in a multiracial cohort of US women. The Global Longitudinal Study of Osteoporosis in Women. NOF 2009.
 145. Siris ES, Adachi JD, Compston J, Gehlbach S, Lindsay R, Saag KG, Silverman SL, et al. Failure to perceive increased risk of fracture in women 55 years and older. The Global Longitudinal Study of Osteoporosis in Women. NOF 2009.
 146. Gehlbach SH, Saag KG, Adachi JD, Adami S, Boonen S, Greenspan S, Netelenbos C, Sambrook PN, Silverman SL, et al. Previous Fractures Increase Risk for Subsequent Fractures at Multiple Sites: Global Longitudinal Study of Osteoporosis in Women. ASBMR 2010.
 147. Hooven FH, Roux C, Adami S, Boonen S, Chapurlat R, Compston JE, Cooper C, Diez-Perez A, Netelenbos JC, Pfeilschifter J, Nika G, Gehlbach SH, Silverman SL. Reasons for stopping anti-osteoporosis medications among postmenopausal women. The Global Longitudinal Study of Osteoporosis in Women. IOF World Congress 2010.
 148. Hooven FH, Boonen S, Adami S, Chapurlat R, Compston JE, Cooper C, Diez-Perez A, Netelenbos JC, Pfeilschifter J, Roux C, Nika G, Gehlbach SH, Silverman SL. Risk factor characteristics of women with incident fractures. The Global Longitudinal Study of Osteoporosis in Women. IOF World Congress 2010.
 149. Moore M, Gehlbach S, Saag KG, Adachi JD, Adami S, Boonen S, Greenspan SL, Netelenbos JC, Sambrook P, Silverman SL, et al. Previous fractures increase risk for subsequent fractures at multiple sites: Global Longitudinal Study of Osteoporosis in Women. NAPCRG 2010.
 150. Silverman SL. Comparison of direct and indirect costs in employees with painful diabetic peripheral neuropathy treated with pregabalin or duloxetine. Presented at ISPOR May 2010.
 151. Silverman SL. Primary Care Efficient Practices in the Care of Patients with Fibromyalgia. Presented at ASPE 2010.
 152. Silverman SL, Obiols AQ, Nasser K, Silver DS. Which FRAX database to use in measuring absolute risk of major osteoporotic fracture in Guatemala? Presented in ASBMR, Toronto, 2010.
 153. Roux C, Hooven FH, Boonen S, Chapurlat RD, Cooper C, Diez-Perez A, LaCroix A, Silverman SL, et al. Burden of non-hip-non-vertebral fractures in postmenopausal women: prospective data from the Global Longitudinal Study of Osteoporosis in Women (GLOW). Presented at ASBMR, Toronto, 2010.
 154. Naegeli A, Burge R, Watts S, Stump T, Gold DT, Silverman SL.

- Modification of the osteoporosis patient assessment questionnaire using item response theory methods. Presented at ASBMR, Toronto, 2010.
155. Gold DT, Silverman SL, Naegeli A, Watts S, Burge R. Attitudes toward compliance of patients participating in a randomized controlled trial. Presented at ASBMR, Toronto, 2010.
 156. Silverman SL, Watts S, Gold DT, Naegeli A, Kanis JA, Burge R. Association of fracture risk and quality of life as measured by the osteoporosis patient assessment questionnaire. Presented at ASBMR, Toronto, 2010.
 157. Ioannidis G, Adachi JD, Pickard L, Chapurlat R, Saag KG, Silverman S, et al for the GLOW Investigators. Health Care Utilization following a fracture: Global Longitudinal study of Osteoporosis in Women (GLOW). ACR 2010.
 158. Silverman S, Wang A, Viswanathan H, et al. Development of a comorbidity index using the FREEDOM trial in women with postmenopausal osteoporosis. San Diego, California. ASBMR 2011.
 159. Compston J, Watts N, Chapurlat R, Cooper C, Boonen S, Grenspan S, Pfeilschifter J, Silverman S, et al. Fracture incidence in obese postmenopausal women: The Global Longitudinal study of Osteoporosis in Women (GLOW). San Diego, California. ASBMR 2011.
 160. Diez-Perez A, Sambrook P, Compston J, Adachi J, Hooven F, Watts N, Silverman S, et al. Clinical characteristics of women who fracture despite anti-osteoporosis medication. The Global Longitudinal study of Osteoporosis in Women (GLOW). San Diego, California. ASBMR 2011.
 161. Ioannidis G, Flahive J, Pickard L, Papaioannou A, Chapurlat R, Saag K, Silverman S, et al. Global health care utilization following a fracture. The Global Longitudinal study of Osteoporosis in Women (GLOW). San Diego, California. ASBMR 2011.
 162. Curtis J, Wyman A, Fitzgerald G, Diez-Perez A, Gehlbach S, Roux C, Saag K, Siris E, Silverman S. Predicting adherence among women participating in the global longitudinal registry of osteoporosis in women. San Diego, California. ASBMR 2011.
 163. Compston J, Premaor M, Flahive J, Siris E, Gehlbach S, Adachi J, Boonen S, Chapurlat R, Diez-Perez A, Hooven F, LaCroix A, Netelenbos C, Pfeilschifter J, Rossini M, Roux C, Saag K, Sambrook P, Silverman S, et al. Effect of co-morbidities on fracture risk: Findings from the Global Longitudinal study of Osteoporosis in Women (GLOW). San Diego, California. ASBMR 2011.
 164. Reynolds K, Viswanathan H, O'Malley C, Muntner P, Harrison T, Cheetham TC, Hsu J, Gold D, Silverman S, et al. Psychometric properties of the osteoporosis-specific morisky medication adherence scale (OS-MMAS) in postmenopausal women with osteoporosis (OP) treated with bisphosphonates (BP). San Diego, California. ASBMR 2011.
 165. Curtis J, Wyman A, Fitzgerald G, Diez-Perez A, Gehlbach S, Roux C, Saag K, Siris E, Silverman S. Predicting adherence among women participating in the Global Longitudinal study of Osteoporosis in Women (GLOW). San Diego, California. ASBMR 2011.

166. Silverman S, Calderon A, Mofield A, et al. Relative importance of attributes that influence osteoporosis decision-making in postmenopausal women. San Diego, California. ASBMR 2011.
167. Compston J, Watts N, Chapurlat R, Cooper C, Boonen S, Greenspan S, Pfeilschifter J, Silverman S, et al. Fracture incidence in obese postmenopausal women: The Global Longitudinal study of Osteoporosis in Women (GLOW). San Diego, California. ASBMR 2011.
168. Gehlbach S, Guggina P, Hooven F, Flahive J, Boonen S, Compston J, Cooper C, Diez-Perez A, Greenspan S, Lindsay R, Netelenbos C, Sambrook P, Silverman S, et al. Factors associated with use of anti-osteoporosis medication. The Global Longitudinal study of Osteoporosis in Women (GLOW). San Diego, California. ASBMR 2011.